Recombinant AAV Vectors for Treating Parkinson's, MSA, Gaucher's Disease - US12605467B2
Summary
USPTO granted patent US12605467B2 to Shanghai Vitalgen Biopharma Co., Ltd. on April 21, 2026, covering recombinant adeno-associated viral (rAAV) vectors encoding aromatic L-amino acid decarboxylase (AADC), glucocerebrosidase (GBA1), and neurotrophic factors (CDNF or GDNF) for treating neurodegenerative disorders including Parkinson's disease, multiple system atrophy, and Gaucher's disease. The patent contains 14 claims and names three inventors.
What changed
USPTO issued patent US12605467B2 to Shanghai Vitalgen Biopharma Co., Ltd. covering recombinant adeno-associated viral (rAAV) vectors carrying nucleotide sequences for aromatic L-amino acid decarboxylase (AADC), glucocerebrosidase (GBA1), and neurotrophic factors (CDNF or GDNF). The vectors are designed for treating neurodegenerative disorders and proteinopathies, specifically Parkinson's disease (PD), multiple system atrophy (MSA), and Gaucher's disease (GD). The patent contains 14 claims and was granted as a B2 (second grant) patent.
Biopharmaceutical and gene therapy developers working on AAV-based treatments for Parkinson's disease, MSA, or Gaucher's disease should review this patent for potential freedom-to-operate concerns. The granted claims cover both single-vector and dual-cistron configurations of the specified therapeutic genes. Inventors are Yezheng Tao, Shin-Shay Tian, and Xiaoping Zhao.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Recombinant AAV vectors for treating neurodegenerative disorders
Grant US12605467B2 Kind: B2 Apr 21, 2026
Assignee
SHANGHAI VITALGEN BIOPHARMA CO., LTD.
Inventors
Yezheng Tao, Shin-Shay Tian, Xiaoping Zhao
Abstract
Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.
CPC Classifications
A61K 48/0058 C07K 14/52 C12N 15/86
Filing Date
2024-10-18
Application No.
18919740
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.